Drug-Induced Hyperglycemia and Diabetes Mellitus

2007 ◽  
pp. 513-527
Author(s):  
Mary McCullen ◽  
Intekhab Ahmed
Keyword(s):  
Diabetes Mellitus ◽  
Drug Induced

Fulminant Type 1 Diabetes Mellitus Associated with Drug Induced Hypersensitivity Syndrome by Zonisamide (Excegran)

2008 ◽  
Vol 70 (5) ◽  
pp. 482-486
Author(s):  
Ikko KAJIHARA ◽  
Asako ICHIHARA ◽  
Jyunko HIGO ◽  
Masato KIDOU ◽  
Mikio TODAKA ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Hypersensitivity Syndrome ◽  
Drug Induced ◽  
Fulminant Type 1 Diabetes ◽  
Fulminant Type

scholarly journals Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Caroline Bartolo ◽  
Victoria Hall ◽  
N. Deborah Friedman ◽  
Chloe Lanyon ◽  
Andrew Fuller ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Fungal Infections ◽  
Case Reports ◽  
Sglt2 Inhibitor ◽  
Sglt2 Inhibitors ◽  
Urogenital Tract ◽  
Hypoglycemic Agents ◽  
Drug Induced ◽  
First Case ◽  
Increased Risk

Abstract Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors are novel hypoglycemic agents which reduce reabsorption of glucose at the renal proximal tubule, resulting in significant glycosuria and increased risk of genital mycotic infections (GMI). These infections are typically not severe as reported in large systematic reviews and meta-analyses of the medications. These reviews have also demonstrated significant cardiovascular benefits through other mechanisms of action, making them attractive options for the management of Type 2 diabetes mellitus (T2DM). We present two cases with underlying abnormalities of the urogenital tract in which the GMI were complicated and necessitated cessation of the SGLT2 inhibitor. Case presentations Both cases are patients with T2DM on empagliflozin, an SGLT2 inhibitor. The first case is a 64 year old man with Candida albicans balanitis and candidemia who was found to have an obstructing renal calculus and prostatic abscess requiring operative management. The second case describes a 72 year old man with Candida glabrata candidemia who was found to have prostatomegaly, balanitis xerotica obliterans with significant urethral stricture and bladder diverticulae. His treatment was more complex due to fluconazole resistance and concerns about urinary tract penetration of other antifungals. Both patients recovered following prolonged courses of antifungal therapy and in both cases the SGLT2 inhibitor was ceased. Conclusions Despite their cardiovascular benefits, SGLT2 inhibitors can be associated with complicated fungal infections including candidemia and patients with anatomical abnormalities of the urogenital tract may be more susceptible to these infections as demonstrated in these cases. Clinicians should be aware of their mechanism of action and associated risk of infection and prior to prescription, assessment of urogenital anatomical abnormalities should be performed to identify patients who may be at risk of complicated infection.

scholarly journals Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36

Blood ◽  
2012 ◽  
Vol 119 (25) ◽  
pp. 6136-6144 ◽  
Author(s):  
Weifei Zhu ◽  
Wei Li ◽  
Roy L. Silverstein
Keyword(s):  
Diabetes Mellitus ◽  
Mouse Models ◽  
Advanced Glycation End Products ◽  
Vascular Complications ◽  
Dependent Manner ◽  
Advanced Glycation ◽  
Drug Induced ◽  
Glycation End Products ◽  
End Products

Abstract Diabetes mellitus has been associated with platelet hyperreactivity, which plays a central role in the hyperglycemia-related prothrombotic phenotype. The mechanisms responsible for this phenomenon are not established. In the present study, we investigated the role of CD36, a class-B scavenger receptor, in this process. Using both in vitro and in vivo mouse models, we demonstrated direct and specific interactions of platelet CD36 with advanced glycation end products (AGEs) generated under hyperglycemic conditions. AGEs bound to platelet CD36 in a specific and dose-dependent manner, and binding was inhibited by the high-affinity CD36 ligand NO2LDL. Cd36-null platelets did not bind AGE. Using diet- and drug-induced mouse models of diabetes, we have shown that cd36-null mice had a delayed time to the formation of occlusive thrombi compared with wild-type (WT) in a FeCl3-induced carotid artery injury model. Cd36-null mice had a similar level of hyperglycemia and a similar level of plasma AGEs compared with WT mice under this condition, but WT mice had more AGEs incorporated into thrombi. Mechanistic studies revealed that CD36-dependent JNK2 activation is involved in this prothrombotic pathway. Therefore, the results of the present study couple vascular complications in diabetes mellitus with AGE-CD36–mediated platelet signaling and hyperreactivity.

scholarly journals Catecholamine metabolism in animals with drug induced diabetes mellitus (Report 2)

1982 ◽  
Vol 32 ◽  
pp. 162
Author(s):  
Takeshi Ohuchi ◽  
Yasuko Ishimura ◽  
Kazuo Minaguchi ◽  
Takeo Tsunematsu ◽  
Motoo Oka
Keyword(s):  
Diabetes Mellitus ◽  
Catecholamine Metabolism ◽  
Drug Induced

scholarly journals Catecholamine metabolism in animals with drug induced diabetes mellitus [report 1]

1981 ◽  
Vol 31 ◽  
pp. 271
Author(s):  
Takeshi Ohuchi ◽  
Yasuko Ishimura ◽  
Kyoji Morita ◽  
Eiichi Tachikawa ◽  
Kazuo Minaguchi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Catecholamine Metabolism ◽  
Drug Induced

Fasting in Ramadan is safe for Individuals Suffering from Type 2 Diabetes Mellitus in Pakistan

2020 ◽  
Author(s):  
Fatima Jehangir
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Care Center ◽  
P Value ◽  
Risk Category ◽  
Drug Induced ◽  
Ramadan Fasting ◽  
Health Care Center

Background: Whether diabetics should fast or not in Ramadan has been a controversial idea since long and the answer even more debatable. It confers safety measures to be known by the diabetics thoroughly, such as when to break the fast and what the hypoglycemic cut offs are. We aimed to determine hypoglycemic events and safety of Ramadan fasting among individuals with Type 2 Diabetes Mellitus (DM). Methods: This was an observational study enrolling diabetics who decided to fast in Ramadan, were aged >18 years, visited the primary health care center in Sikanderabad and Clifton clinic and gave consent to participate in the study. The exclusion criteria was Type 1 Diabetes Mellitus, Gestational diabetes, drug induced Diabetes and Maturity Onset Diabetes of the Young. A total of 103 participants were included in the study. Data was captured pre-Ramadan, during Ramadan and post-Ramadan in the year 2019. Multivariate Logistic regression was computed and chi-square taken for association of risk factors with hypoglycemia. P-value <0.05 was considered significant. Results: Mean HbA1c before Ramadan was 9.2%+2.1 and after Ramadan 7.7%+1.4 (P-value<0.05) showing a reduction of 1.5%. Mean weight of the patients before Ramadan was 68.3kg+1.6 and during Ramadan 64.8kg+1.4(p-value <0.00) showing a dip of 3.5 kg however mean weight 1 month after Ramadan was 66.5kg+14.9 depicting a rise again of 1.8kgs. Higher the risk category of American Heart Association, those who had hypoglycemic events before Ramadan and those on basal-bolus combination insulin had more hypoglycemic events (p-value <0.05). Conclusion: Fasting in Ramadan shows a major reduction in weight (3.5kg) as well as corrects hyperglycemia (1.5%). However, hypoglycemia was attributed to high risk patients only hence Ramadan fasting proved to be quite safe in individuals with Type 2 DM.

Sign in / Sign up

Export Citation Format

Share Document